Stockley’s Drug Interactions is the most indispensable source of drug interaction information available.
It provides expertly authored advice on managing drug interactions, and will quickly and reliably help you decide your best course of action.
SubscribeContent Updates
With over 4,500 detailed records, access drug-drug, drug-herb, drug-food interactions and much more
Featuring a concise summary at the start of each record, you can also discover the clinical evidence, mechanism, importance and management of each interaction
Contains detailed, fully referenced and international information with an unrivalled depth of content
*based on average data in the last 12 months
Stockley’s Drug Interactions update with new and revised monographs.
This update contains 2 new monographs, and 57 existing monographs have been updated. The chapter on the calcium channel blockers has been completely re-validated and updated.
Stockley’s Drug Interactions update with new and revised monographs.
For this update, several sections have been completely re-validated and updated, including those on abiraterone, the cannabinoids, and methotrexate. New drugs that have been added include lorcaserin, pimavanserin, pitolisant, telotristat ethyl, and tezacaftor. This update contains 42 new monographs, and 149 existing monographs have been updated.
Stockley’s Drug Interactions update with new and revised monographs.
For this update, new classification tables of inhibitors and substrates of the drug transporter proteins BCRP, MATE, OAT, OATP, and OCT, based on clinical pharmacokinetic data have been added, along with a new table of drugs that lower the seizure threshold. Several sections have been completely re-validated and updated, including those on HCV drugs and the HIV-protease inhibitors. This update contains 39 new monographs, and 692 existing monographs have been updated.
This update contains 16 new monographs, and 654 existing monographs have been updated. Cariprazine, ertugliflozin, obeticholic acid, and semaglutide have been added for this update. Several sections have been completely re-validated and updated, including those on the bile acids and metformin.
Stockley’s Drug Interactions update with new and revised monographs.
This update a new monoclonal antibodies chapter has been created, bringing all the monographs for these drugs into one place within the publication. The sections on the NRTIS and NNRTIs have been completely re-validated and updated. New drugs added for this update include abemaciclib, eluxadoline, lesinurad, ribociclib, sacubitril, and selexipag.
For June, 67 new interactions have been added, and 64 existing interactions have been updated.
